Axogen Q3 2026 earnings

AXGN · 2026-10-28 07:04 BMO ET · 8-K on SEC

Revenue growth accelerated to 26.2% with net income turning positive, supported by a $225 million equity raise and the BioCircuit acquisition.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$75.8M+26.2%+8.7%Ex. 99.1, income statement
EPS (GAAP)$0.04+300%+0.01Ex. 99.1, income statement
EPS (adjusted)$0.21+75%+0.09Ex. 99.1, income statement
Net income$2.3M+228%+$2.3MEx. 99.1, income statement
Adj. EBITDA$13.4M+45%+$5.0MEx. 99.1, income statement
Adj. EBITDA margin17.7%+2.3 pp+5.6 ppEx. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 74.8% (prior 76.6%, change -1.8 pp)
  • Operating expenses $55.8M (+26.3% YoY)
  • One-offs in the quarter Loss on extinguishment of debt $16.8M; BioCircuit transaction and integration costs $2.0M
  • Effective tax rate 1.4% (prior-year 3.2%, year-to-date 1.1%)
  • Non-GAAP bridge Adds back non-cash stock-based compensation ($24.4M), BioCircuit transaction and integration costs ($2.0M), and loss on extinguishment of debt ($16.8M).

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents, restricted cash, and investments$350.1M$113.4M$103.6M+$236.7M
Revenue from BioCircuit acquisition$7M00+$7M

Guidance

MetricGuidePrior guideChange
Full-year revenueat least $290Mat least $279M+$11M
Organic revenue (excl. BioCircuit)at least $283Mat least $279M+$4M
Gross marginat least 73%at least 73%unchanged
Free cash flowpositivepositiveunchanged

What drove it

  • Revenue story Revenue grew 26.2% YoY to $75.8M, driven by broad-based growth across Extremities, Oral Maxillofacial & Head and Neck, and Breast, and includes $7M from the BioCircuit acquisition.
  • EPS story GAAP EPS turned positive to $0.04, driven by net income of $2.3M, while adjusted EPS rose to $0.21 due to improved operating income and the removal of non-cash and one-time items.
  • One-off check Loss on extinguishment of debt $16.8M (non-recurring); BioCircuit transaction and integration costs $2.0M (non-recurring).

The good

  • Revenue growth accelerated to 26.2% YoY
  • Adjusted EBITDA margin expanded to 17.7%
  • Cash balance increased to $350.1M

The bad

  • Gross margin contracted 1.8 pp YoY to 74.8%
  • Operating expenses increased 26.3% YoY

The ugly

  • none

Open questions

  • What specific factors caused the gross margin contraction?
  • What are the specific integration costs associated with BioCircuit?
Full release

Earnings: AXGN — filed 2026-10-28

Axogen, Inc. (AXGN) · Form 8-K, Item 2.02 · Filed · SEC filing

Axogen, Inc. Reports Third Quarter 2026 Financial Results

Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million

ALACHUA and TAMPA, FL – October 28, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2026.

Third Quarter Financial Results

• Revenue was $75.8 million, an increase of 26.2% compared to $60.1 million in the third quarter of 2025.

• Gross margin was 74.8% compared to 76.6% in the third quarter of 2025.

• Net income was $2.3 million, or $0.04 per share, compared to $0.7 million, or $0.01 per share for the third quarter of 2025.

• Adjusted net income was $13.1 million, or $0.21 per share, as compared to $6.1 million, or $0.12 per share for the third quarter of 2025.

• Adjusted EBITDA was $13.4 million, compared to $9.2 million for the third quarter of 2025.

• Cash and cash equivalents, restricted cash, and investments as of September 30, 2026 was $350.1 million, as compared to $113.4 million as of June 30, 2026, an increase of $236.7 million.

“We are delighted with our third-quarter and year-to-date revenue performance and the progress we continue to make across each of Axogen’s strategic plan priorities,” said Michael Dale, President and CEO of Axogen, Inc. “Our strong growth across all markets, continues to validate our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our 2026 revenue guidance and longer-term strategic objectives.”

Summary of Business Highlights

• Year-to-date revenue growth through the third quarter of 2026 was broad-based across Extremities, Oral Maxillofacial & Head and Neck, and Breast, driven by 20% plus year-over-year account productivity, expanding sales force coverage, and improving commercial insurance coverage and payment.

• Received positive coverage decisions from Elevance and Aetna; commercial payer coverage for Avance is now approximately 96% of covered lives in the United States.

• We closed an upsized public offering with the sale of 5,646,500 shares of common stock and receipt of $225 million of net proceeds. $200 million of the net proceeds were used to fund the BioCircuit acquisition and $1.9 million were used to fund transaction related expenses, with the remaining funds available for general corporate purposes.

• On October 1, 2026, we completed the acquisition of BioCircuit Technologies, Inc. (“BioCircuit”), a privately held medical device company and developer of NerveTape®.

• Based on positive clinical study outcomes, we have made the decision to initiate Prostate market development beginning in 2027. Axogen management will host a prostate specific investment-community conference call and webcast on November 9, 2026 at 9:00 a.m. Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event will be available on the Investors page of the Company’s website at www.axogeninc.com.

2026 Financial Guidance

For 2026, we expect full-year revenue of at least $290 million, representing growth of at least 29%, including at least $7 million revenue from the BioCircuit acquisition. Excluding BioCircuit, we expect organic revenue to be at least $283 million, representing growth of at least 26%. We continue to expect gross margin to be at least 73%, and positive free cash flow for the full-year.

Conference Call

The Company will host a conference call and webcast for the investment community today at 8:00 a.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the Company’s website at www.axogeninc.com and clicking on the webcast link.

Following the conference call, a replay will be available in the Investors section of the Company’s website at www.axogeninc.com under Investors.

About Axogen

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen’s product portfolio includes Avance®

(acellular nerve allograft-arwx), Avance®

Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, Avive+ Soft Tissue Matrix®, and NerveTape®.

For more information, visit www.axogeninc.com.

Financial statements

Income Statement

Three Months Ended — (in thousands, except share and per share amounts)

Three Months Ended – September 30, 2026Three Months Ended – September 30, 2025Nine Months Ended – September 30, 2026Nine Months Ended – September 30, 2025
Revenues75,83460,082207,022165,304
Cost of goods sold19,10314,08953,42842,360
Gross profit56,73145,993153,594122,944
Costs and expensesSales and marketing30,36125,68089,82170,529
Costs and expensesResearch and development8,9507,56525,05620,509
Costs and expensesGeneral and administrative16,46510,83642,75029,983
Costs and expensesTotal costs and expenses55,77644,081157,627121,021
Costs and expensesIncome (loss) from operations9551,912-4,0331,923
Other income (expense)Investment income1,4313192,985816
Other income (expense)Interest expense-1-1,757-696-5,984
Other income (expense)Loss on extinguishment of debt-16,849
Other income (expense)Change in fair value of debt derivative liabilities209531
Other income (expense)Other (expense) income, net-5125-173167
Other income (expense)Total other income (expense), net1,379-1,204-14,733-4,470
Other income (expense)Net income (loss)2,334708-18,766-2,547
Other income (expense)Weighted average common shares outstanding — basic55,158,42446,494,59853,437,63345,905,069
Other income (expense)Weighted average common shares outstanding — diluted61,525,78949,088,43653,437,63345,905,069
Other income (expense)Net income (loss) per common share — basic0.040.02-0.35-0.06
Other income (expense)Net income (loss) per common share — diluted0.040.01-0.35-0.06

Income Statement

Common Stock — (in thousands, except share amounts)

Common Stock – SharesCommon Stock – AmountAdditional Paid-in CapitalAccumulated DeficitTotal Shareholders' Equity
Three Months Ended September 30, 2026Balance at June 30, 202653,656,293537583,783-328,063256,257
Three Months Ended September 30, 2026Net income2,3342,334
Three Months Ended September 30, 2026Issuance of common shares5,646,50057224,972225,029
Three Months Ended September 30, 2026Stock-based compensation8,7948,794
Three Months Ended September 30, 2026Issuance of restricted and performance stock units, net of shares withheld for withholding taxes9,507-174-174
Three Months Ended September 30, 2026Exercise of stock options412,22433,8603,863
Three Months Ended September 30, 2026Balance at September 30, 202659,724,524597821,235-325,729496,103
Nine Months Ended September 30, 2026Balance at December 31, 202547,199,797472435,338-306,963128,847
Nine Months Ended September 30, 2026Net loss-18,766-18,766
Nine Months Ended September 30, 2026Issuance of common shares10,246,500103358,178358,281
Nine Months Ended September 30, 2026Stock-based compensation24,40324,403
Nine Months Ended September 30, 2026Issuance of restricted and performance stock units, net of shares withheld for withholding taxes1,130,19511-9,458-9,447
Nine Months Ended September 30, 2026Exercise of stock options and employee stock purchases under the ESPP1,148,0321112,77412,785
Nine Months Ended September 30, 2026Balance at September 30, 202659,724,524597821,235-325,729496,103
Three Months Ended September 30, 2025Balance at June 30, 202545,765,290457406,334-294,515112,276
Three Months Ended September 30, 2025Net income708708
Three Months Ended September 30, 2025Stock-based compensation5,4245,424
Three Months Ended September 30, 2025Issuance of restricted and performance stock units81,9251-1
Three Months Ended September 30, 2025Exercise of stock options270,06832,3942,397
Three Months Ended September 30, 2025Balance at September 30, 202546,117,283461414,151-293,807120,805
Nine Months Ended September 30, 2025Balance at December 31, 202444,148,836441394,726-291,260103,907
Nine Months Ended September 30, 2025Net loss-2,547-2,547
Nine Months Ended September 30, 2025Stock-based compensation13,50113,501
Nine Months Ended September 30, 2025Issuance of restricted and performance stock units1,301,06213-13
Nine Months Ended September 30, 2025Exercise of stock options and employee stock purchases under the ESPP667,38575,9375,944
Nine Months Ended September 30, 2025Balance at September 30, 202546,117,283461414,151-293,807120,805

Income Statement

EBITDA & Adjusted EBITDA — (in thousands, except share and per share amounts)

Three Months Ended – September 30, 2026Three Months Ended – September 30, 2025Nine Months Ended – September 30, 2026Nine Months Ended – September 30, 2025
Net income (loss)2,334708-18,766-2,547
Depreciation and amortization expense1,6941,7305,1165,248
Investment income-1,431-319-2,985-816
Income tax expense (benefit)32-622204
Interest expense11,7576965,984
EBITDA - non-GAAP2,6303,814-15,7197,873
EBITDA margin - non-GAAP3.56.3-7.64.8
Non-cash stock-based compensation expense8,7945,42424,40313,501
BioCircuit transaction and integration costs1,9691,969
Loss on extinguishment of debt16,849
Adjusted EBITDA - non-GAAP13,3939,23827,50221,374
Adjusted EBITDA margin - non-GAAP17.715.413.312.9

Income Statement

Adjusted Net Income — (in thousands, except share and per share amounts)

GAAP ResultsNon-cash Stock-based Compensation ExpenseAdjusted Results
RevenuesGAAP Results60,082Non-cash Stock-based Compensation ExpenseAdjusted Results60,082
Cost of goods sold14,089-70613,383
Gross profit45,99370646,699
Costs and expensesSales and marketing25,680-1,52424,156
Costs and expensesResearch and development7,565-1,0476,518
Costs and expensesGeneral and administrative10,836-2,1478,689
Costs and expensesTotal costs and expenses44,081-4,71839,363
Costs and expensesIncome from operations1,9125,4247,336
Other income (expense)Investment income319319
Other income (expense)Interest expense-1,757-1,757
Other income (expense)Change in fair value of debt derivative liabilities209209
Other income (expense)Other income, net2525
Other income (expense)Total other expense, net-1,204-1,204
Other income (expense)Net income7085,4246,132
Other income (expense)Weighted average common shares outstanding - diluted49,088,43649,088,43649,088,436
Other income (expense)Net income per common share - diluted0.010.110.12

Income Statement

Adjusted Net Income — (in thousands, except share and per share amounts)

Nine Months Ended September 30, 2026 – GAAP ResultsNine Months Ended September 30, 2026Nine Months Ended September 30, 2026 – Non-cash Stock-based Compensation ExpenseNine Months Ended September 30, 2026 – BioCircuit Transaction and Integration CostsNine Months Ended September 30, 2026 – Loss on Extinguishment of DebtNine Months Ended September 30, 2026 – Dilutive Shares Impact(1)Nine Months Ended September 30, 2026 – Adjusted Results
RevenuesGAAP Results207,022Non-cash Stock-based Compensation ExpenseBioCircuit Transaction and Integration CostsLoss on Extinguishment of DebtAdjusted Results207,022
Cost of goods sold53,428-2,82450,604
Gross profit153,5942,824156,418
Costs and expensesSales and marketing89,821-5,73784,084
Costs and expensesResearch and development25,056-5,04020,016
Costs and expensesGeneral and administrative42,750-10,802-1,96929,979
Costs and expensesTotal costs and expenses157,627-21,579-1,969134,079
Costs and expenses(Loss) income from operations-4,03324,4031,96922,339
Other income (expense)Investment income2,9852,985
Other income (expense)Interest expense-696-696
Other income (expense)Loss on extinguishment of debt-16,84916,849
Other income (expense)Other expense, net-173-173
Other income (expense)Total other (expense) income, net-14,73316,8492,116
Other income (expense)Net (loss) income-18,76624,4031,96916,84924,455
Other income (expense)Weighted average common shares outstanding - diluted53,437,63353,437,63353,437,63353,437,6336,097,03759,534,670
Other income (expense)Net (loss) income per common share - diluted-0.350.460.040.32-0.040.41

Income Statement

Adjusted Net Income — (in thousands, except share and per share amounts)

GAAP ResultsNon-cash Stock-based Compensation ExpenseDilutive Shares Impact(1)Adjusted Results
RevenuesGAAP Results165,304Non-cash Stock-based Compensation ExpenseAdjusted Results165,304
Cost of goods sold42,360-1,40640,954
Gross profit122,9441,406124,350
Costs and expensesSales and marketing70,529-3,42267,107
Costs and expensesResearch and development20,509-2,79617,713
Costs and expensesGeneral and administrative29,983-5,87724,106
Costs and expensesTotal costs and expenses121,021-12,095108,926
Costs and expensesIncome from operations1,92313,50115,424
Other income (expense)Investment income816816

Balance Sheet

(in thousands, except share and per share amounts)

September 30, 2026December 31, 2025
Current assetsCash and cash equivalents328,88835,548
Current assetsRestricted cash2,0004,000
Current assetsInvestments19,1805,980
Current assetsAccounts receivable, net of allowance for doubtful accounts of $770 and $948, respectively34,00826,169
Current assetsInventory49,06342,373
Current assetsPrepaid expenses and other assets4,9536,352
Current assetsTotal current assets438,092120,422
Current assetsProperty and equipment, net81,94681,783
Current assetsOperating lease right-of-use assets13,39412,732
Current assetsIntangible assets, net7,9106,750
Current assetsOther assets, net8,997
Current assetsTotal assets550,339221,687
Current liabilitiesAccounts payable and accrued expenses34,62621,184
Current liabilitiesCurrent maturities of long-term lease obligations1,8302,372
Current liabilitiesTotal current liabilities36,45623,556
Current liabilitiesLong-term debt, net of debt discount and financing fees48,387
Current liabilitiesLong-term lease obligations17,63916,870
Current liabilitiesDebt derivative liabilities3,886
Current liabilitiesOther long-term liabilities141141
Current liabilitiesTotal liabilities54,23692,840
Shareholders’ equityCommon stock, $0.01 par value per share; 100,000,000 shares authorized; 59,724,524 and 47,199,797 shares issued and outstanding, respectively597472
Shareholders’ equityAdditional paid-in capital821,235435,338
Shareholders’ equityAccumulated deficit-325,729-306,963
Shareholders’ equityTotal shareholders’ equity496,103128,847
Shareholders’ equityTotal liabilities and shareholders’ equity550,339221,687

Cash Flow

Nine Months Ended — (in thousands)

Nine Months Ended – September 30, 2026Nine Months Ended – September 30, 2025
Cash flows from operating activities:Net loss-18,766-2,547
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Depreciation4,7875,027
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Amortization of right-of-use assets1,305294
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Amortization of intangible assets329221
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Amortization of debt discount and deferred financing fees68666
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Provision for bad debts4358
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Loss on disposal of equipment26
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Change in fair value of debt derivative liabilities-531
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Investment gains, net-191-238
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Loss on extinguishment of debt16,849
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Stock-based compensation expense24,40313,501
Change in operating assets and liabilities:Accounts receivable-7,843-7,028
Change in operating assets and liabilities:Inventory-6,690-7,398
Change in operating assets and liabilities:Prepaid expenses and other assets1,399-619
Change in operating assets and liabilities:Other assets, net-1,989
Change in operating assets and liabilities:Accounts payable and accrued expenses13,359-2,985
Change in operating assets and liabilities:Operating lease obligations-1,724-833
Change in operating assets and liabilities:Cash paid for interest portion of financing lease obligations-4-3
Change in operating assets and liabilities:Other long-term liabilities-111
Change in operating assets and liabilities:Net cash provided by (used in) operating activities25,322-2,226
Cash flows from investing activities:Purchase of property and equipment-5,074-2,498
Cash flows from investing activities:Purchase of investments-27,209-13,723
Cash flows from investing activities:Proceeds from sale of investments14,2008,000
Cash flows from investing activities:Purchases of equity investments held at cost-7,008
Cash flows from investing activities:Cash payments for intangible assets-1,306-1,138
Cash flows from investing activities:Net cash used in investing activities-26,397-9,359

Cash Flow

Nine Months Ended — (in thousands)

Nine Months Ended – September 30, 2026Nine Months Ended – September 30, 2025
Cash flows from financing activities:Proceeds from issuance of common stock359,622
Cash flows from financing activities:Payment of stock issuance costs-1,341
Cash flows from financing activities:Repayment of long-term debt-48,585
Cash flows from financing activities:Fees paid to lender related to debt extinguishment-20,498

Cash Flow

Free Cash Flow

Nine Months Ended – September 30, 2026Nine Months Ended – September 30, 2025
Net cash provided by (used in) operating activities25,322-2,226
Purchase of property and equipment-5,074-2,498
Cash payments for intangible assets-1,306-1,138
Free cash flow18,942-5,862

Cautionary Statements Concerning Forward-Looking Statements... (truncated)ment strategies and objectives; our strategic investments, including the expected benefits and opportunities of such investments; our expectations around the potential positive impact on our business of expanded coverage and reimbursement for peripheral nerve injuries using synthetic conduits or allografts; our ability to sustain growth, operate profitably, generate positive cash flows, and fund our market development initiatives. These statements are based on management’s current expectations and estimates of trends and economic factors in the markets in which we are active. Words such as “expects,” “anticipates,” “objectives,” “targets,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Actual results or events could differ materially from those described in any forward-looking statements as a result of factors, including, without limitation, the risks and challenges associated with integrating BioCircuit and the realization of the anticipated benefits of the acquisition, disruptions from global supply chain issues, inflation, hospital staffing challenges, product development timelines, regulatory processes, financial performance, surgeon adoption rates, market awareness of our products, the estimated total addressable market, as well as those risk factors described under Part I, Item 1A, “Risk Factors,” in our most recent Annual Report on Form 10-K and other risks and uncertainties that may be detailed from time to time in reports filed by the Company with the SEC. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. Forward-looking statements speak only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements.

About Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, and Adjusted EBITDA, which further excludes non-cash stock-based compensation expense, BioCircuit transaction and integration costs, and the loss on extinguishment of debt, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income and Adjusted Net Income Per Common Share - diluted which excludes non-cash stock-based compensation expense, BioCircuit transaction and integration costs, and the loss on extinguishment of debt from Net Income (Loss) and Net Income (Loss) Per Common Share - diluted. Additionally, we use the non-GAAP financial measure of Free Cash Flow which consists of net cash provided by operating activities, less expenditures for property and equipment, and intangible assets.

These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated.

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (ii) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.

Axogen, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

Axogen, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except share and per share amounts)

Axogen, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

Axogen, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

Axogen, Inc.

Condensed Consolidated Statements of Changes in Shareholders’ Equity

(unaudited)

(in thousands, except share amounts)

Axogen, Inc.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(unaudited)

(in thousands, except share and per share amounts)

Axogen, Inc.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(unaudited)

(in thousands, except share and per share amounts)

Axogen, Inc.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(unaudited)

(in thousands, except share and per share amounts)

__________

(1)

Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.

Axogen, Inc.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(unaudited)

(in thousands, except share and per share amounts)

__________

(1)... (truncated)ering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Axogen earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.